The immunologic release of SRS-Arat with intravenously administered antigen is described. Hetrazan effectively inhibits the antigen-induced release of SRS-Arat in a dose of 20 mg/kg iv. In this concentration, it has no influence on the bioassay system and does not prevent effective antibody-antigen interaction. Hetrazan does not produce an irreversible inhibition and must be present at the time of antibody-antigen interaction to effectively prevent the formation and release of SRS-Arat. Suppression of the 4-hour PCA reaction in the rat with Hetrazan plus mepyramine maleate and methysergide suggests that SRS-Arat may be a permeability factor involved in this reaction.
|Original language||English (US)|
|Number of pages||6|
|Journal||Proceedings of the Society for Experimental Biology and Medicine|
|State||Published - Jan 1968|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)